Editorial Board ::: Recent Patents on Anti-Cancer Drug Discovery

ISSN: 2212-3970 (Online)
ISSN: 1574-8928 (Print)


Volume 11, 4 Issues, 2016


Download PDF Flyer




Recent Patents on Anti-Cancer Drug Discovery

This journal supports open access

Aims & ScopeAbstracted/Indexed in

Ranking and Category:
  • 35th of 254 in Pharmacology & Pharmacy
  • 46th of 211 in Oncology

Submit Abstracts Online Submit Manuscripts Online

Editor-in-Chief:
Khurshid Zaman
Bentham Science Publishers
USA


View Full Editorial Board

Subscribe Purchase Articles Order Reprints

Current: 3.533
5 - Year: 2.638

Editorial Board

Editor-in-Chief:

Khurshid Zaman
Bentham Science Publishers
USA



Associate Editor(s):

Patrick Legembre
University of Rennes-1
EA SeRAIC-4427/IRSET
Rennes
France

Anna Sapino
University of Turin
Turin
Italy


Regional Editor(s):

Amedeo Amedei (Biography
Amedeo Amedei

Amedeo Amedei in 1996 he graduated with full marks and honours in Biology at Florence University. He started his scientific career studying the role of Th1/Th2 lymphocytes in GVHD, atopic dermatitis and kidney rejection. After he examined the role of Helicobacter pylori-specific immune response in gastric diseases. In 2003 began his doctor’s degree in "Clinical and Sperimental Medicine". In 2005 he became researcher at Department of Experimental and Clinical Medicine (University of Florence), where in 2015 he was appointed Associate Professor. Recently, the Prof. Amedei has focused his scientific interests on the cancer immunology. The great quality of his international profile is documented by scientific production: 126 peer reviewed articles (3474 Citations), 6 book chapters and one patent. The Prof. Amedei is serving as an editorial board member of 56 international journals and carries out activities as scientific reviewer for international research projects of private and public entities.

)

University of Florence
Firenze
Italy

Andrew M. Chan (Biography
Andrew M. Chan

Dr. Andrew M. Chan is a Professor and Chief of the Cancer Biology & Experimental Therapeutics Programme at the School of Biomedical Sciences of The Chinese University of Hong Kong. He obtained his Ph.D. degree from The Institute of Cancer Research in London in 1989 and conducted postdoctoral training at the US National Cancer Institute. He joined the Mount Sinai School of Medicine as an assistant professor and was recruited to the Medical College of Wisconsin as a full professor. Dr. Chan published 61 peer-reviewed articles in high impact journals including Science, Nature Genetics, PNAS, Cancer Cell, and Blood.

)

The Chinese University of Hong Kong
Shatin
Hong Kong

Irena Kostova (Biography
Irena Kostova

Graduated from Mendeleev Univ., Moscow. PhD and DSc Theses by MU-Sofia. Editor: METAL-BASED DRUGS; ASIAN CHEM LETT; INT J DRUG DISCOV; INT J CURR CHEM; REC PAT ANTI–CANCER DRUG DISCOV; J PHARMA&PHARM SCI. Member of Editorial Boards: ANTI-CANCER AGENTS MED CHEM; WORLD J VIROL; IND J PURE&APPL PHYS; THE OPEN CANCER JOURNAL; REC PAT ANTI-INF DRUG DISCOV; INFECT & DRUG RES; BRIT J MED MED RES; INT J CHEM; INT J ENVIR SCI; DATASET PAPERS CHEM; PEERTECHZ J MED CHEM RES.

Published over 130 papers (citations>3000; IF>140; h-index: 27). More details: https://www.researchgate.net/profile/Irena_Kostova2

https://scholar.google.com/citations?user=PPateJQAAAAJ&hl=en

)

Medical University
Sofia
Bulgaria

Jianyu Rao
University of California at Los Angeles
CA
USA

Takuya Watanabe
Watanabe Internal Medicine Aoyama Clinic
Niigata
Japan

Vasso Apostolopoulos
Victoria University
Melbourne
Australia

Chung-Yi Chen (Biography
Chung-Yi Chen

President Chen obtained PhD in 1999 at Kaohsiung Medical University. Currently teaches in Fooyin University, as most young is also the most senior professors and deans. The past 20 years, he has his scientific interests focused on life-threatening diseases, including traditional Chinese medicine used for cancer research. President Chen was just over 45 years old, but his work has more than 200 papers, Taiwan one of the young talents. Professor Chen was invited more than 70 kinds of Journal editorial boards. Professor Chen won numerous awards at home and abroad, from 2015, was awarded the lifetime achievement award.

)

Fooyin University
Kaohsiung
Taiwan

Terry Lichtor (Biography
Terry Lichtor

Terry Lichtor, MD, PhD is a practicing neurosurgeon. He has a number of research interests, and his brain tumor work is largely focused on the development of a DNA vaccine for treatment of primary and metastatic intracerebral tumors. In particular Dr. Lichtor has shown that vaccines prepared by transfer of DNA from the tumor into a highly immunogenic cell line stimulates an antitumor immune response which may be efficacious in the treatment of patients with brain tumors. Other research interests include developing a passive immunotherapeutic strategy for treatment of Alzheimer’s Disease. In addition, he has been involved in the development of a non-invasive MRI technique to measure intracranial pressure and brain compliance, and has been exploring the efficacy of this modality in managing a variety of patients with neurologic problems where intracranial pressure is an issue. Dr. Lichtor is a member of the neurosurgery faculty at Rush University Medical Center in Chicago, Illinois.

)

Rush University Medical Center
IL
United States

Hongbin Sun (Biography
Hongbin Sun

Dr. Sun obtained a doctorate (Ph.D.) in Medicinal Chemistry from China pharmaceutical University in 1995. Currently Dr. Sun is a Professor in China pharmaceutical University. He has published more than 180 scientific publications and is the inventor of more than 30 patent applications. Dr. Sun’s major research interest is target verification and drug discovery for metabolic diseases and cancer. The leading drug candidate developed by Dr. Sun is Vicagrel (an anti-platelet agent in phase I clinical trial).

)

China Pharmaceutical University
Nanjing
China

Alfredo Budillon (Biography
Alfredo Budillon

Dr. Budillon graduated in Medicine and passed the Specialty Certification in Oncology at University Federico II, Naples, Italy. He obtained the PhD in Oncology from University G. D’Annunzio of Chieti, Italy, and a Master degree in Health economy, Management and Bioethics. Dr. Budillon is the chief of Experimental Pharmacology, National Cancer Institute G. Pascale, Naples, Italy. He is also Adjunct Professor in Temple University’s College of Science and Technology, Philadelphia, PA, USA, and author of more that 130 publications and of a patent. He is also member of the Editorial Advisory Board of Reviews On Recent Clinical Trials, published by Bentham Science.

)

National Cancer Institute - G. Pascale
Napoli
Italy

Zhe-Sheng Chen (Biography
Zhe-Sheng Chen

Dr. Chen obtained a doctorate (Ph.D.) in Pharmacology from the Kagoshima University, Japan. Dr. Chen also holds an MD degree from Guangdong Medical and Pharmaceutical College and a Master degree in Toxicology from Sun Yat-Sen Medical University, China. Currently Dr. Chen is a Professor at St. John’s University College of Pharmacy and Health Sciences. Dr. Chen is also a director of Institute for Biotechnology at St. John’s University. He has published more than 180 scientific publications. Dr. Chen is the founding Editor in Chief of Journal of Cancer Research Updates and is also the Editor-in-Chief of Journal of New Developments in Chemistry, an editor of African Journal of Pharmacy and Pharmacology. He is also an editorial board member of 26 journals and a reviewer of more than 170 peer reviewed journals. As a consultant to pharmaceutical, biotechnology and health industry organizations, Dr. Chen commands invitations for more than 150 presentations, keynote addresses, and conference chairman. Dr. Chen is also a grant reviewer of NIH, Chinese National Natural Science Foundation (China), The Genesis Oncology Trust (New Zealand), National Science Centre (Poland), The Government of the Hong Kong Special Administrative Region (HKSAR) Grant, Hong Kong (China), the Hungarian Scientific Research Fund (OTKA) (Hungary), the Netherlands Organisation for Scientific Research (NWO) (Netherlands), and the Czech Science Foundation (Czech) etc.

)

St. John's University
NY
USA

Luca Munaron (Biography
Luca Munaron

Dr. Luca Munaron obtained his Ph.D. in Physiology from the University of Milan (Italy) and is currently Associate Professor in Physiology at the University of Turin (Italy).

He is a member of the Editorial Board of several international journals and served as an Editor for special issues.

Dr. Munaron published more than 70 full papers on indexed journals and its work reached more than 1800 citations.

)

University of Torino
Torino
Italy

J.-Y. WINUM (Biography
J.-Y. WINUM

Dr. Winum received his PhD in chemistry from the University of Montpellier (France), in 1998. He then worked as a postdoctoral fellow in the Chemistry Department of Georgetown University (Washington, DC) and in the Organic Chemistry Department of the University of Geneva (Switzerland). In 1999, he joined the Department of Chemistry of the University of Montpellier, where he is now an Associate Professor. He has published more than 135 scientific papers and is a named inventor of 6 patents. Beside being Regional Editor of Recent Patents in Anti-cancer Drug Discovery, he is also associate editor of Journal of Enzyme Inhibition and Medicinal Chemistry and editorial board member of Expert Opinion on Therapeutic Patents, Anticancer Agents in Medicnal Chemistry and Current Organic Chemistry.

)

University of Montpellier
Montpellier
France


Book Review Editor(s):

Sergei N. Orlov
Laboratory of Biomembranes
Moscow
Russia


Editorial Board Members:

R.J. Akhurst
University of California
CA
USA

R. Aneja
Georgia State University
GA
USA

D.C. Baumgart
University of Berlin
Berlin
Germany

I. Blanco
Catalan Institute of Oncology
Barcelona
Spain

R. Brosh
National Institutes of Health
MD
USA

K. Camphausen
National Cancer Institute
MD
USA

C. Carlo-Stella
University of Milan
Milan
Italy

J. Chen
Vanderbilt University
MN
USA

A. Ciampolillo
University of Bari
Bari
Italy

W.M. Dai
The Hong Kong University of Science and Technology
Kowloon
Hong Kong

C. Dumontet
Universite Claude Bernard Lyon
Lyon
France

Z. Estrov
University of Texas MD Anderson Cancer Center
TX
USA

L. Fu
Sun Yat-sen University
Guangzhou
China

L. Gamet-Payrastre
INRA, Laboratoire des Xénobiotiques
Toulouse
France

P. Grieb
Mossakowski Med. Res. Ctr. Polish Acad. of Sci.
Warsaw
Poland

T.-C. He
The University of Chicago Medical Center
IL
USA

W. Hu
University of Texas MD Anderson Cancer
TX
USA

H. Hung
National Cancer Centre of Singapore
Singapore

Y. Keisari
Tel Aviv University
Tel Aviv
Israel

Y.-H. Kim
Korea University Anam Hospital Cancer Center
Seoul
South Korea

M. Kriajevska
University of Leicester
Leicester
UK

C. La Porta
University of Milan
Milan
Italy

H. Lawnicka
Medical University of Lodz
Lodz
Poland

P. Limonta (Biography
P. Limonta

Dr. Limonta obtained a Degree in Pharmaceutical Chemistry and Technology and a Degree in Pharmacy from the University of Milano, Italy. She also holds a Postdoctoral Degree in Pharmacology and a Postdoctoral Degree in Experimental Endocrinology from the University of Milano, Italy. She has been Postdoctoral fellow in Biology of Reproduction at the Population Council, Center for Biomedical Research, New York (1983-1984).

Currently, Dr. Limonta is Associate Professor of Applied Biology, at the University of Milano. She has published 90 scientific peer-reviewed publications, most of them in the field of molecular oncology.

She is currently Editorial Advisory board Member of the journal 'Recent Patents on Anti-Cancer drug Discovery'.

)

University of Milan
Milan
Italy

H.H. Luu
University of Chicago
IL
USA

F. Mannello
University "Carlo Bo" of Urbino
Urbino
Italy

J.A. McCubrey
East Carolina University
NC
USA

O. Micheau (Biography
O. Micheau

Dr. Micheau studied molecular biology and obtained a Ph.D. in 1999 at the University of Bourgogne, Dijon, France. He moved the same year to Jürg Tschopp's laboratory at the department of biochemistry of the University of Lausanne, Switzerland, where he identified the molecular mechanisms underlying TNFR1 death signaling. In 2003 he was awarded a full tenured INSERM position at the University of Bourgogne-Franche-Comté in the Lipid Nutrition and Cancer department (LNC U866), and was appointed director of research in the INSERM unit U866 in 2015. His current research focuses on the characterization of TRAIL signaling.

)

INSERM
Dijon
France

P. Moreau (Biography
P. Moreau

Prof. Pascale Moreau obtained a Master Degree in Biophysicochemistry and Cellular and Molecular Biology, and a Ph.D in Chemistry and Physicochemistry of Compounds with Biological Interest, from the University of Orléans (France). She joined Pr. Victor A. Snieckus’s group at Waterloo University (Canada), working on macrocycles synthesis and directed ortho-metalation. During a second post-doctoral position at Bristol-Myers-Squibb (Marne-la-Vallée, France) she focused on asymmetric synthesis. In 1996, she moved to Blaise Pascal University (Clermont-Ferrand, France) working on hemisynthesis of rebeccamycin derivatives. Her current research is devoted to the development of new bioactive heteroaromatic compounds.

http://iccf.univ-bpclermont.fr/spip.php?rubrique44&lang=en

)

Blaise Pascal University
Clermont-Ferrand II
France

J. Neuzil
Griffith University
Queensland
Australia

Y.-P. Pang
Mayo Clinic Cancer Center
MN
USA

M. Provenzano
University Hospital Zurich
Zurich
Switzerland

D. Ribatti
University of Bari
Bari
Italy

P. Russo
IRCCS “San Raffaele Pisana”
Rome
Italy

N.A. Saunders (Biography
N.A. Saunders

Associate Professor Nicholas Saunders trained as a pharmacologist at the University of Western Australia under the supervision of Professor Rodney Minchin and Professor Ken Illett. Dr Saunders was then awarded a Fogarty Visiting Fellowship to pursue postdoctoral studies at the National Institute of Environmental Health Sciences in the USA under the supervision of Professor Anton Jetten. In 1993, Dr Saunders was approached by Professor Ian Frazer to return to Australia and set up the Epithelial Pathobiology Group. Since establishing his research group, Dr Saunders has attracted more than $12 million in competitive research funding and has been the recipient of a Lions Medical Research Foundation Senior Research Fellowship, a Garnett Passe and Rodney Williams Memorial Foundation Principal Research Fellowship and is a current Cancer Council Queensland Senior Research Fellowship. Ass Prof Saunders is currently Head of the Epithelial Pathobiology Group within the University of Queensland Diamantina Institute.

)

University of Queensland
Queensland
Australia

A. Shtil (Biography
A. Shtil

Dr. A. Shtil received his MD degree in Orenburg State Medical Institute and PhD in Moscow Research Institute of Otorhinolaryngology. In 1994-2002 he worked in the University of Illinois at Chicago, Lee Moffitt Cancer Center and Sloan-Kettering Cancer Institute, studying the mechanisms of multidrug resistance and altered drug response in cancer (with I.Roninson, W.Dalton and K.Scotto). After returning to Blokhin Cancer Center he established a new laboratory of tumor cell death with broad interests in cancer biology. The laboratory is studying the molecular mechanisms of cytocidal effects of small molecular weight compounds as perspective anticancer drug candidates. Our particular interest is novel DNA ligands, including the derivatives of anthraquinone and porphyrins that target the double helix and complex DNA structures. We also investigate the anti-apoptotic and pro-proliferation protein kinase Pim-1, the druggable target for newly developed indole based inhibitors. International cooperation includes the European Consortium “Protein kinases – Novel Drug Targets of Post Genomic Era” and contacts with grroups in the United States, France, Japan and Taiwan. Dr. Shtil has authored 150 scientific papers, review articles and a number of patents. He is member of editorial boards in four international journals.

)

Blokhin Cancer Center
Moscow
Russia

A. Toninello
University of Padova
Padova
Italy

N. Tuncel (Biography
N. Tuncel

Dr. Neşe Tunçel received her BS in Pharmacy in 1970 and her PhD in Medical Physiology in 1982 from Ankara University, Turkey. She has been served as a Professor in the Department of Physiology and Neurophysiology, Faculty of Medicine, Eskis􏰁ehir Osmangazi University, and she was retired in April 2016. She has 95 scientific publications. She also serves as a member of the Editorial boards of several academic journals including Current Pharmaceutical Design, Medicinal Chemistry, Recent Patents on Anti-Cancer Drug Discovery, The Open Cancer Journal, Biomedical Review and Adipobiology, Current Clinical pharmacology. She has also served in the Editorial Advisory Board of Peptides in the period 1998-2010 and, Immunology, Endocrine and Metabolic Agents for three years.

)

Eskisehir Osmangazi University
Eskisehir
Turkey

L. Dalla Via (Biography
L. Dalla Via

Dr. Dalla Via obtained the degree in Biological Sciences with full marks cum laude and a doctorate (Ph.D.) in Biochemistry and Biophysics from the University of Padova, Italy. Currently Dr. Dalla Via is associate professor in the Department of Pharmaceutical and Pharmacological Sciences of the University of Padova. She has published 96 scientific publications.

)

University of Padova
Padova
Italy

M. Watanabe (Biography
M. Watanabe

Dr.Watanabe graduated from Yokohama National University, Faculty of Engineering, and Mie University, Faculty of Medicine. He obtained a doctor in Medicine from Mie University. He is also a guest professor, Yokohama City University. He has published more than 100 scientific publications.

)

Yokohama National University
Tokiwadai
Japan

D. Wolowiec
Medical University of Wroclaw
Wroclaw
Poland

D.J. Yang
The University of Texas M.D. Anderson Cancer Center
TX
USA

I. X.-M. Yuan (Biography
I. X.-M. Yuan

Dr. Xi-Ming Yuan received his M.D. in 1984 from Jilin Medical College in China and a Ph.D. degree in internal medicine 1997 from Linkoping University, Sweden. Year 2006 he has been appointed Associate Professor in Experimental Pathology by Faculty of Medicine and Health Sciences, Linköping University. He has published more than 70 scientific publications in SCI that are cited > 1572 times with a h-index 23.

)

Linköping University Hospital
Linkoping
Sweden

J. Zhou (Biography
J. Zhou

Dr. Zhou obtained a doctorate (Ph.D.) in Cell Biology from Emory University. Currently Dr. Zhou is a Professor in the Nankai University College of Life Sciences. He is also a Professor and Director in the Shandong Normal University Institute of Biomedical Sciences. Dr. Zhou has published more than 80 scientific publications. He was the Editor of Microtubule Protocols and Multi-Drug Resistance in Cancer, both published by the Humana Press.

)

Nankai University
Tianjin
China

A.M. Almerico
University of Palermo
Palermo
Italy

A. Arcaro (Biography
A. Arcaro

Alexandre Arcaro is a group leader at Bern University Hospital in Switzerland. He graduated in biology at the University of Lausanne (Switzerland) in 1992 and obtained a Ph.D. in natural sciences from the University of Fribourg (Switzerland) in 1995. He was then a postdoctoral fellow at the Ludwig Institute for Cancer Research, University College London, United Kingdom, from 1996 to 1997 and at the Ludwig Institute for Cancer Research, Lausanne Branch, from 1998 to 2000. From 2000 to 2003 he was then a lecturer at Imperial College Faculty of Medicine, London, United Kingdom. He was a group leader at the University Children’s Hospital Zurich, Switzerland, from 2003 to 2009. His research work is focused on the study of receptor tyrosine kinase signaling and PI3K isoforms in human cancer.

)

Bern University Hospital
Bern
Switzerland

A. Berrebi
Kaplan Medical Center
Rehovot
Israel

W. Bornmann
The University of Texas M.D. Anderson Cancer Center
TX
USA

J. Brunel (Biography
J. Brunel

Jean Michel Brunel was graduated from the School of Chemistry of Marseille (France) in 1991. He obtained his Ph.D. degree in 1994 from Université Aix Marseille in the field of asymmetric organophosphorus chemistry. In 1994, he joined the group of Pr. H. B. Kagan (Université Paris Sud) as a postdoctoral fellow working on the enantioselective catalytic oxidation of sulfides. In 1997, he joined the CNRS as Chargé de Recherche and is now working at the Centre de Recherche en Cancérologie de Marseille. His research program is focused on the development of novel classes of antimicrobial and anticancer agents.

)

Aix-Marseille University
Marseille
France

Y. Cao
MTC Karolinska Institute
Stockholm
Sweden

N. Cerqueira
University of Porto
Porto
Portugal

X. Chen
National Institutes of Health
MD
USA

L. Cocco (Biography
L. Cocco

Dr. Cocco is M.D. from the University of Chieti, School of Medicine. After being Visiting Scientist at the Beatson Inst. Cancer Res., Glasgow and at the AFRC Babraham Institute, Cambridge, U.K. is presently Professor, Chair of Anatomy and Head of Cellular Signalling Laboratory at the University of Bologna. Editorial Board: Advances in Biological Regulation Editor-in-Chief of Advances in Biological Regulation, is Board Member of Recent Patents on Anti-Cancer Drug Discovery, Cellular Signalling, Journal of Cellular Biochemistry Founder and First Co-Chairman of the new series of Gordon Research Conference “Signal Transduction Within the Nucleus” He has authored more than 300 full length papers in peer reviewed Journal and has discovered the nuclear signalling via inositol lipid cycle

)

University of Bologna
Bologna
Italy

Q.P. Dou
Wayne State University
MI
USA

M.V. Dwek
University of Westminster
London
UK

R.A. Franklin
Brody Sch. of Med. at East Carolina University
NC
USA

S. Fulda
Goethe-University Frankfurt
Frankfurt
Germany

E.J. Gao
Shenyang Institute of Chemical Technology
Shenyang
China

D. Grierson
University of British Columbia
Vancouver, BC
Canada

J.W. Ho
The Chinese University of Hong Kong
Shatin
Hong Kong

C.-M.E. Huang
University of Califonia
CA
USA

K.-I. Inoue
International University of Health and Welfare
Otawara
Japan

M. Khan
Biomedical Research Institute
Coventry
UK

S.V. Kozlov
NCI at Frederick
MD
USA

A. Kumar
CSIR-Central Drug Research Institute
Lucknow
India

M.D. Lacher
T cell Therapeutics, Inc.
CA
USA

E. Lech-Maranda
Institute of Hematology and Transfusion Medicine
Warsaw
Poland

K.P. Lu (Biography
K.P. Lu

Kun Ping Lu, MD, PhD, is a Professor at Harvard Medical School and the Chief of the Division of Translational Therapeutics at Beth Israel Deaconess Medical Center. He discovers a unique phosphorylation-specific proline isomerase, Pin1 that helps protect against Alzheimer’s disease and whose aberrant activation helps promote the development of cancer. Based on these discoveries, his laboratory is working to develop an antibody therapy for the early diagnosis and treatment of Alzheimer’s and traumatic brain injury, and Pin1 chemical inhibitors to overcome drug resistance in cancer treatments.

)

Harvard Medical School
MA
USA

B.A. Lwaleed
University of Southampton
Southampton
UK

M.P. Marques
University of Coimbra
Coimbra
Portugal

M. McKeage
The University of Auckland
Auckland
New Zealand

S. Mocellin (Biography
S. Mocellin

Prof. Simone Mocellin obtained his MD degree at the University of Padova, where he specialized in General Surgery in 1998 and he's got a PhD doctorate in Surgical Oncology in 2002. For two years (1999-2001) he worked at the Surgery Branch of the National Cancer Institute of Bethesda (Maryland, USA). Currently he works as consultant surgeon at the Surgical Oncology branch of the Istituto Oncologico Veneto (IOV-IRCCS) of Padova, Italy. He is also professor of surgery at the Dept. Surgery Oncology and Gastroenterology of the University of Padova, Italy. He is the author of more than 160 articles published in peer-review international medical journals. His main interest is surgical oncology with special regard to the surgical treatment and translational research in the fields of cutaneous melanoma, soft tissue sarcomas and gastrointestinal cancers.

)

University of Padova
Padova
Italy

J.-S. Nam (Biography
J.-S. Nam

Dr. Jeong-Seok Nam obtained a doctorate (Ph.D.) in Veterinary Medicine from Seoul National University, Seoul, South Korea. Dr. Nam's research focuses on understanding and targeting cancer metastasis. He is working as an associate professor in school of life sciences, Gwangju Institute of Science and Technology, Gwangju, South Korea. He has published more than 80 scientific publications. He is currently the editorial board member of this journal (Recent Patents on Anti-Cancer Drug Discovery), published by Bentham Science Publishers.

)

Gwangju Institute of Science and Techonology
Gwangju
Korea

A. Nishikawa
National Institute of Health Sciences
Tokyo
Japan

E. Papadimitriou
University of Patras
Patras
Greece

M.D. Pujol
University of Barcelona
Barcelona
Spain

T. Robak
Medical University of Lodz
Lodz
Poland

D. Santini
University Campus Bio-Medico
Rome
Italy

E. Segal-Bendirdjian (Biography
E. Segal-Bendirdjian

Received her MD from Necker Hospital (Paris Descartes University, France) and her PhD in Molecular and cellular Biology from Pierre and Marie Curie University (Paris, France). After working in Molecular and Biological Pharmacology in Gustave-Roussy Institute (Villejuif, France), she obtained a position as a research scientist at CNRS. She joined Saint-Louis Hospital (Paris, France) in 1998 where she became a team leader as a Research Director working on the pharmacological and physiological regulation of the telomerase expression and activity in an INSERM Unit. She joined Paris Descartes University in 2010 where she became the head of INSERM UMR-S 1007 named "Cellular Homeostasis and Cancer".

)

Université Paris Descartes
Paris
France

H. Stepien (Biography
H. Stepien

Dr. Stepien obtained in 1976 a doctorate (Ph.D) in Medicine from the Faculty of Medicine , Medial University of Lodz (Poland). In 1980-1982 he received post doctoral scholarship in the Institute for Biomedical Research University of Texas at Austin (USA). Dr. Stepien also holds visting professor position at McMaster University , Hamilton, Ontario (Canada). Currently he is Professor of Medicine and Head of the Chair of Endocrinology Medical University of Lodz. He has published more than 200 publications in the field of neuroimmunoendocrinology. Prof. Stepien is an active member of Polish Society of Neuroendocrinology, Society of Endocrinology (USA) and European Society of Endocrinology .

)

Medical University of Lodz
Lodz
Poland

G. Tonini (Biography
G. Tonini

Prof. Tonini, MD PhD, is Full Professor of Medical Oncology and Chief of the Division of Medical Oncology at Campus Bio-Medico University Hospital of Rome. He is Coordinator of the Degree Course in Medicine and Surgery, Director of the Post-Graduated School in Medical Oncology, Professor at Phd School of Integrated Biomedical Science and Bioethics and Director of the Translational Oncology Research Laboratory.

Current fields of investigation include clinical and molecular aspects of solid tumors, with particular attention to colorectal cancer, biliary tract cancer, bone metastases and palliative care in cancer.

Prof. Tonini is member of the Editorial Board or Editor in Chief of numerous high-ranked international journals and he has authored over 350 peer-reviewed manuscripts, reviews and book chapters on International Journals.

)

University Campus Bio-Medico
Rome
Italy

J. Tyndall
University of Otago
Dunedin
New Zealand

G. Vitale
University of Milan
Milan
Italy

T. Watanabe
Tokyo University School of Medicine
Tokyo
Japan

K.K. Wong
The University of Texas M. D. Anderson Cancer Center
TX
USA

K. Ye
State University of New York
AR
USA

G. Zauli
Institute for Maternal and Child Health - IRCCS “Burlo Garofolo”
Trieste
Italy

Y. Zou
University of California
San Diego, CA
USA

A. Amin (Biography
A. Amin

Amr Amin has completed his PhD at University of Illinois at Chicago, and received a post-doctoral training in the field of molecular genetics at the University of Pennsylvania School of Medicine. He started his academic career at UAE University where he serves now as a Full Professor of Cell Biology. Amr’s research focuses on ways to control cancer, particularly liver cancer. He published many research articles and reviews and serves as reviewer and as an editorial member of many specialized peer-reviewed journals. He is also a member of many specialized societies and the sole recipient of national and international scientific awards.

)

United Arab Emirates University
Al-Ain
UAE

A. Bateman
Research Institute of McGill University Health Centre
Montreal, QC
Canada

A. Bishayee
American University of Health Sciences
CA
USA

M. Bracke
Gent University Hospital
Gent
Belgium

B. Bussolati
University of Turin
Torino
Italy

M. Caraglia
Second University of Naples
Naples
Italy

F. Chen
Fudan University
Shanghai, P.R
China

P. Chieffi
Second University of Naples
Naples
Italy

Z. Culig
Innsbruck Medical University
Innsbruck
Austria

H.S. Duggal
United Indian Health Services Arcata
CA
USA

F. Entschladen
MetaVi Labs
Witten
Germany

G. Fritz
Heinrich Heine University Düsseldorf
Düsseldorf
Germany

M. Galanski (Biography
M. Galanski

Prof. Dr. Galanski obtained a doctorate (Ph.D.) in Chemistry from the University of Heidelberg, Germany. He holds the position of Associate Professor at the Institute of Inorganic Chemistry of the University of Vienna, Austria. Dr. Galanski has (co)authored more than 150 publications in the field of bioinorganic chemistry with a focus on the development of platinum-based anticancer drugs.

)

University of Vienna
Vienna
Austria

J. Golab
The Medical University of Warsaw
Warsaw
Poland

F.H. Hausheer
BioNumerik Pharmaceuticals Inc.
TX
USA

A. Honda
Tokyo Medical University
Ibaraki
Japan

H.-S. Huang (Biography
H.-S. Huang

Dr. Huang obtained a doctorate (Dr. rer. nat.) in Pharmacy from the University of Regensburg, Germany. Dr. Huang was former dean of School of Pharmacy, and head of the Department of Research and Development in NDMC and director of Department of Pharmacy Practice, Tri-Service General Hospital/NDMC. Currently Dr. Huang is a Professor in College of Medical Science and Technology, Taipei Medical University also an Adjunct Professor in NDMC. He has published more than 90 scientific publications and is a named inventor of 30 issued U.S and Taiwan patents.

Dr. Huang is currently the Editorial Advisory Board of this journal, published by Bentham Science Publishers.

)

National Defense Medical Center
Taipei
Taiwan

K. Kakudo
Wakayama Medical University
Wakayama
Japan

S.G. Kim
Seoul National University
Seoul
Korea

G. Kremmidiotis
Bionomics Limited
Thebarton
Australi

J. Kusari
Allergan Pharmaceuticals
CA
USA

H.C. Lai
University of Washington
WA
USA

M. Lei
Medical College of Wisconsin
MI
USA

R. Lucas
Georgia Health Sciences University
GA
USA

S. Madhusudan
University of Nottingham
Nottingham
UK

J.M.P. Martin
Universidad Autonoma de Madrid
Madrid
Spain

L. Messori
University of Florence
Sesto Fiorentino
Italy

F. Mollinedo
CSIC-University of Salamanca
Salamanca
Spain

N. Neamati
University of Southern California
CA
USA

M. Ohh
University of Toronto
Toronto, ON
Canada

E. Petridou
Athens University Medical School
Athens
Greece

D. Raucher
University of Mississippi Medical Center
MS
USA

L. Ronconi
National University of Ireland Galway
Galway
Ireland

M. Sattler
Dana-Farber Cancer Institute
MA
USA

M.S. Sheikh
Upstate Medical University
NY
USA

X. Sun (Biography
X. Sun

Dr Xueying Sun obtained MD and PhD from Shandong University in 1994. He is currently holding a professorial position at the Department of Surgery, the Affiliated Hospital of Harbin Medical University, and a position of Honorary Senior Research Fellow at Department of Molecular Medicine & Pathology, FMHS, University of Auckland. His present research and professional specialities include tumor hypoxia, cancer molecular targeted therapy, cellular signalling and non-coding RNAs. He was a winner of World Health Organization Fellowship (1999-2000) and Wellcome Trust Leave Fellowship (2001-2005). He has published over 200 research articles in peer-viewed journals including 120 articles in Science Citation Index journals. He is also a member of Editorial board of five academic journals, and a member of the review panels for National Natural Scientific Foundation, Ministry of Science and Technology and Ministry of Education of China.

)

Harbin Medical University
Harbin
P.R. China

E. Tulchinsky
University of Leicester
Leicester
UK

H. Uemura
Yokohama City University
Yokohama
Japan

T. Vogt
University of Saarland
Homburg/Saar
Germany

K.G. Wiman
Karolinska Institute
Stockholm
Sweden

W. Xu
Shandong University
Jinan Shandong
China

N. Yoshimi
University of Ryukyus
Okinawa
Japan

Z.-F. Zhang
UCLA School of Public Health
CA
USA


Advertisement

Related Journals




Related eBooks


Webmaster Contact: urooj@benthamscience.org Copyright © 2016 Bentham Science